^
Association details:
| Biomarker: | HER-2 negative |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | paclitaxel (Bcl2 inhibitor, Tubulin polymerization promoter) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
Invasive Breast Cancer: HER-2 negative...Preferred regimens…Taxanes…Paclitaxel…
Source:
Title:
Paclitaxel and Bavituximab in Treating Patients With HER2-Negative Metastatic Breast Cancer
Excerpt:
...- Histologically or cytologically confirmed, Her-2 negative breast cancer with evidence of metastatic disease...
Trial ID:
Source:
Title:
Paclitaxel and BKM120 Before Surgery in Treating Patients With Stage II or III Estrogen Receptor-Positive and HER2-Negative Breast Cancer
Excerpt:
...- Clinical stage II or III ER-positive, HER2-negative breast cancer with complete surgical excision of the breast cancer as the treatment goal....
Trial ID:
More C2 evidence
Source:
Title:
BCT 1702 (CHARIOT): Patients with high-risk primary triple negative breast cancer who have had anthracycline-based chemotherapy will receive Ipilimumab and Nivolumab with weekly paclitaxel, followed by definitive surgery and further treatment with Nivolumab to evaluate the safety, feasibility and efficacy of this treatment.
Excerpt:
......
Trial ID:
Source:
Title:
Efficacy and safety of Antinib hydrochloride capsule combined with Paclitaxel for Injection (Albumin Bound) for first-line treatment of triple negative breast cancer
Excerpt:
...Pathologically confirmed hormone receptor (ER and PR negative) and HER2 negative advanced breast cancer; if there are multiple pathological results, the definition of triple negative breast cancer is the final subtype of the last biopsy pathological molecular subtype; 4. ...
Trial ID:
Source:
Title:
Phase Ib/II Trial of BEZ235 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer
Excerpt:
...- Females with Breast cancer that is histologically or cytologically confirmed, HER2 negative and locally advanced or metastatic as confirmed by radiology...
Trial ID:
Source:
Title:
Phase II clinical study of carrelizumab combined with albumin-binding paclitaxel in advanced triple negative breast cancer after first-line treatment
Excerpt:
......
Trial ID:
Source:
Title:
Safety and Efficacy Study of Eribulin in Combination With Bevacizumab for Second-line Treatment HER2- MBC Patients
Excerpt:
...- Histologically confirmed Human Epidermal Growth Factor Receptor 2-Negative adenocarcinoma of the breast with documented progression of disease per investigator assessment following or during first-line treatment with Bevacizumab in combination with Paclitaxel for MBC; patients can have measurable or non-measurable disease....
Trial ID:
Source:
Title:
Genetic Testing in Predicting Response to Paclitaxel in Women With Breast Cancer
Excerpt:
...- HER2/neu negative or positive -...
Trial ID:
Source:
Title:
A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation
Excerpt:
...- HER2 negative disease, and a known hormone receptor status...
Trial ID:
Source:
Title:
Fasting Mimicking Diet Program to ImpRovE ChemoTherapy in Hormone Receptor Postive (HR+), HER2- Breast Cancer
Excerpt:
......
Trial ID:
Source:
Title:
Pilot Study to Evaluate Reparixin With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC)
Excerpt:
...Patients with histologic or cytologic diagnosis of breast cancer with evidence of metastatic disease with documented HER-2 negative status and eligible for treatment with paclitaxel....
Trial ID:
Less C2 evidence
Source:
Title:
Impact of the Relative Dose Intensity of Neoadjuvant Chemotherapy With Anthracycline Followed by Taxane on the Survival of Patients With Human Epidermal Growth Factor Receptor 2-negative Breast Cancer: The JONIE1 Study
Published date:
01/30/2021
Excerpt:
This randomized phase II trial included 188 patients with human epidermal growth factor receptor 2 (HER2)-negative BC treated with anthracycline followed by paclitaxel as NAC….The 5-year overall survival rate was 91.2% and 76.3%, when RDI ≥85% and <85%, respectively (p=0.015)....Maintaining the RDI of NAC is crucial for achieving the survival benefit in selected patients with HER2-negative BC.
DOI:
10.21873/anticanres.14863
Source:
Title:
A Randomized Phase II Study of Sequential Eribulin Versus Paclitaxel Followed by FAC/FEC as Neoadjuvant Therapy in Patients with Operable HER2-Negative Breast Cancer
Published date:
11/03/2020
Excerpt:
We conducted a 1:1 randomized open-label phase II study comparing eribulin versus paclitaxel followed by 5-fluorouracil, either doxorubicin or epirubicin, and cyclophosphamide (FAC/FEC) in patients with operable HER2-negative breast cancer….For the paclitaxel and eribulin groups, the 5-year event-free survival (EFS) rates were 81.8% and 74.0% (HR, 1.549; 95% CI, 0.817 to 2.938; p = .3767), and the 5-year OS rates were 100% and 84.4% (HR, 5.813; 95% CI, 0.647 to 52.208; p = .0752), respectively....As neoadjuvant therapy for operable HER2-negative breast cancer, eribulin followed by FAC/FEC is not superior to paclitaxel followed by FAC/FEC and is associated with a higher incidence of neutropenia-related serious AEs.
Secondary therapy:
FEC; FAC
DOI:
10.1002/onco.13581
